Clinical Trial Update: HCL001 Cell Injection for Decompensated Cirrhosis: A Phase I/II Trial [Phase 1, Phase 2]

View source ↗

Summary

This is an update on a Phase 1/2 cell therapy trial (HCL001) for decompensated cirrhosis, with enrollment ongoing by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Cirrhosis

Drugs mentioned

• HCL001 Cell Injection (HCL001)

Snippet

Sponsor: Shanghai Huicun Medical Technology Co., Ltd. | Conditions: Decompensated Cirrhosis | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION